Ignasi Oliveras1, Ana Sánchez-González1, Daniel Sampedro-Viana1, Maria Antonietta Piludu2, Cristóbal Río-Alamos1, Osvaldo Giorgi2, Maria G Corda2, Susana Aznar3, Javier González-Maeso4, Cristina Gerbolés1, Gloria Blázquez1, Toni Cañete1, Adolf Tobeña1, Alberto Fernández-Teruel5. 1. Department of Psychiatry and Forensic Medicine, Institute of Neurosciences, Universidad Autónoma de Barcelona, 08193 Bellaterra, Barcelona, Spain. 2. Department of Life and Environmental Sciences, Section of Pharmaceutical, Pharmacological and Nutraceutical Sciences, University of Cagliari, 09124, Cagliari, Italy. 3. Research Laboratory for Stereology and Neuroscience, Bispebjerg and Frederiksberg Hospitals, Copenhagen, Denmark. 4. Department of Physiology and Biophysics, Virginia Commonwealth University School of Medicine, Richmond, Virginia, 23298, USA. 5. Department of Psychiatry and Forensic Medicine, Institute of Neurosciences, Universidad Autónoma de Barcelona, 08193 Bellaterra, Barcelona, Spain. albert.fernandez.teruel@uab.cat.
Abstract
RATIONALE: Animal models with predictive and construct validity are necessary for developing novel and efficient therapeutics for psychiatric disorders. OBJECTIVES: We have carried out a pharmacological characterization of the Roman high- (RHA-I) and low-avoidance (RLA-I) rat strains with different acutely administered propsychotic (DOI, MK-801) and antipsychotic drugs (haloperidol, clozapine), as well as apomorphine, on prepulse inhibition (PPI) of startle and locomotor activity (activity cages). RESULTS: RHA-I rats display a consistent deficit of PPI compared with RLA-I rats. The typical antipsychotic haloperidol (dopamine D2 receptor antagonist) reversed the PPI deficit characteristic of RHA-I rats (in particular at 65 and 70 dB prepulse intensities) and reduced locomotion in both strains. The atypical antipsychotic clozapine (serotonin/dopamine receptor antagonist) did not affect PPI in either strain, but decreased locomotion in a dose-dependent manner in both rat strains. The mixed dopamine D1/D2 agonist, apomorphine, at the dose of 0.05 mg/kg, decreased PPI in RHA-I, but not RLA-I rats. The hallucinogen drug DOI (5-HT2A agonist; 0.1-1.0 mg/kg) disrupted PPI in RLA-I rats in a dose-dependent manner at the 70 dB prepulse intensity, while in RHA-I rats, only the 0.5 mg/kg dose impaired PPI at the 80 dB prepulse intensity. DOI slightly decreased locomotion in both strains. Finally, clozapine attenuated the PPI impairment induced by the NMDA receptor antagonist MK-801 only in RLA-I rats. CONCLUSIONS: These results add experimental evidence to the view that RHA-I rats represent a model with predictive and construct validity of some dopamine and 5-HT2A receptor-related features of schizophrenia.
RATIONALE: Animal models with predictive and construct validity are necessary for developing novel and efficient therapeutics for psychiatric disorders. OBJECTIVES: We have carried out a pharmacological characterization of the Roman high- (RHA-I) and low-avoidance (RLA-I) rat strains with different acutely administered propsychotic (DOI, MK-801) and antipsychotic drugs (haloperidol, clozapine), as well as apomorphine, on prepulse inhibition (PPI) of startle and locomotor activity (activity cages). RESULTS: RHA-I rats display a consistent deficit of PPI compared with RLA-I rats. The typical antipsychotic haloperidol (dopamine D2 receptor antagonist) reversed the PPI deficit characteristic of RHA-I rats (in particular at 65 and 70 dB prepulse intensities) and reduced locomotion in both strains. The atypical antipsychotic clozapine (serotonin/dopamine receptor antagonist) did not affect PPI in either strain, but decreased locomotion in a dose-dependent manner in both rat strains. The mixed dopamine D1/D2 agonist, apomorphine, at the dose of 0.05 mg/kg, decreased PPI in RHA-I, but not RLA-I rats. The hallucinogen drug DOI (5-HT2A agonist; 0.1-1.0 mg/kg) disrupted PPI in RLA-I rats in a dose-dependent manner at the 70 dB prepulse intensity, while in RHA-I rats, only the 0.5 mg/kg dose impaired PPI at the 80 dB prepulse intensity. DOI slightly decreased locomotion in both strains. Finally, clozapine attenuated the PPI impairment induced by the NMDA receptor antagonist MK-801 only in RLA-I rats. CONCLUSIONS: These results add experimental evidence to the view that RHA-I rats represent a model with predictive and construct validity of some dopamine and 5-HT2A receptor-related features of schizophrenia.
Entities:
Keywords:
Activity; Antipsychotic drugs; Genetically based rat model; Predictive validity; Prepulse inhibition; Propsychotic drugs; Roman high- and low-avoidance rats; Schizophrenia
Authors: J Sallés; M López de Jesús; O Goñi; A Fernández-Teruel; P Driscoll; A Tobeña; R M Escorihuela Journal: Psychopharmacology (Berl) Date: 2001-03-01 Impact factor: 4.530
Authors: M Guitart-Masip; B Johansson; T Cañete; A Fernández-Teruel; A Tobeña; L Terenius; L Giménez-Llort Journal: Neuroscience Date: 2007-10-11 Impact factor: 3.590
Authors: Justin M Saunders; Alaina M Jaster; Hiba Z Vohra; Mario de la Fuente Revenga; Jennifer Jimenez; Alberto Fernández-Teruel; Jennifer T Wolstenholme; Patrick M Beardsley; Javier González-Maeso Journal: Psychopharmacology (Berl) Date: 2021-08-04 Impact factor: 4.530